CNBC Investing Club

Drug stocks are sliding on fears of Zantac lawsuits — here's what it means for JNJ

Packages of Zantac, a popular medication which decreases stomach acid production and prevents heartburn, sit on a shelf at a drugstore on September 19, 2019 in New York City.
Drew Angerer | Getty Images News | Getty Images

Several drug stocks are getting hit today on concerns of exposure to litigation related to Zantac, a heartburn medicine that was removed from the U.S. markets in 2020 after the Food and Drug Administration determined that impurities found in some samples that could potentially cause cancer.